Coagulation Factor Replacement via Plasma Proteins

Coagulation factor replacement via plasma proteins is a therapeutic approach involving the administration of specific blood clotting factors to individuals with deficiencies in these proteins. These factors can be derived from human plasma (plasma-derived products) or produced using recombinant DNA technology (recombinant products). This therapy is crucial for managing bleeding disorders like hemophilia A and B, and other congenital or acquired coagulopathies, restoring hemostasis by replenishing the missing or deficient clotting factors.

Other names

Plasma-derived clotting factorsRecombinant clotting factorsFactor VIII replacementFactor IX replacementProthrombin complex concentrate (PCC)

Replaces deficient or absent coagulation factors, restoring the coagulation cascade and enabling clot formation.